First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...

TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

Profound Medical (PROF) announced superiority on the prespecified, primary safety endpoint in the Level 1 post-market CAPTAIN randomized controlled trial comparing the TULSA Procedure with robotic ...

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

The median fraction of the gland reaching ablative temperatures on intra-procedural MRI thermometry was 78% (IQR 71-85), with 68% of cases comprising whole gland ablation and 32% sub-total ablation: ...

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is ...

Transurethral ultrasound ablation (TULSA) procedures are performed using the TULSA-PRO system when treating people who have prostate disease, including an enlarged prostate and prostate cancer. There ...

TORONTO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company developing AI-powered, incision-free ...

Detailed price information for Profound Medical Corp (PROF-Q) from The Globe and Mail including charting and trades.